Screening for Fabry disease and Hereditary ATTR amyloidosis in idiopathic small‐fiber and mixed neuropathy

Introduction: In this study we assessed the value of genetic screening for Fabry disease (FD) and hereditary ATTR amyloidosis in patients with idiopathic small‐fiber neuropathy (SFN) or mixed neuropathy in a clinical setting. Methods: This was a Nordic multicenter study with 9 participating centers. Patients with idiopathic SFN or mixed neuropathy were included. Genetic sequencing of the TTR and GLA genes was performed. Results: There were 172 patients enrolled in the study. Genetic screening was performed in 155 patients. No pathogenic mutations in the TTR gene were found. A single patient had a possible pathogenic variant, R118C, in the GLA gene, but clinical investigation showed no firm signs of FD. Discussion: Screening for hereditary ATTR amyloidosis and FD in patients with idiopathic SFN or mixed neuropathy without any additional disease‐specific symptoms or clinical characteristics in a Nordic population appears to be of little value in a clinical setting. Muscle Nerve 59:354–357, 2019

[1]  T. Levine,et al.  Incidence of nonamyloidogenic mutations in the transthyretin gene in patients with autonomic and small fiber neuropathy , 2018, Muscle & nerve.

[2]  Chin‐Chang Huang,et al.  A prospective, observational study of patients with uncommon distal symmetric painful small-fiber neuropathy , 2017, PloS one.

[3]  H. Canhão,et al.  Genetic Screening of Mutations Associated with Fabry Disease in a Nationwide Cohort of Juvenile Idiopathic Arthritis Patients , 2017, Front. Med..

[4]  E. Parati,et al.  Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features , 2016, Current Treatment Options in Neurology.

[5]  H. Smeets,et al.  No Fabry Disease in Patients Presenting with Isolated Small Fiber Neuropathy , 2016, PloS one.

[6]  B. Hazenberg,et al.  First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy , 2016, Current opinion in neurology.

[7]  David Adams,et al.  Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP , 2016, Current opinion in neurology.

[8]  M. Ikram,et al.  The epidemiology and risk factors of chronic polyneuropathy , 2015, European Journal of Epidemiology.

[9]  N. Staff,et al.  Impairments and comorbidities of polyneuropathy revealed by population-based analyses , 2015, Neurology.

[10]  J. Oliveira,et al.  The alpha-galactosidase A p.Arg118Cys variant does not cause a Fabry disease phenotype: data from individual patients and family studies. , 2015, Molecular genetics and metabolism.

[11]  A. Rolfs,et al.  Idiopathic Small Fiber Neuropathy: Phenotype, Etiologies, and the Search for Fabry Disease , 2014, Journal of clinical neurology.

[12]  C. Miranda,et al.  Prevalence of Fabry's disease within hemodialysis patients in Spain. , 2014, Clinical nephrology.

[13]  J. Hoeijmakers,et al.  Incidence and prevalence of small-fiber neuropathy , 2013, Neurology.

[14]  P. Elliott,et al.  Prevalence of Anderson–Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson–Fabry Disease Survey , 2011, Heart.

[15]  M. Kaps,et al.  Frequency of Fabry disease in patients with small‐fibre neuropathy of unknown aetiology: a pilot study , 2011, European journal of neurology.

[16]  J. Ferro,et al.  Mutations of the GLA Gene in Young Patients With Stroke: The PORTYSTROKE Study—Screening Genetic Conditions in PORTuguese Young STROKE Patients , 2010, Stroke.

[17]  R. Desnick,et al.  High incidence of later-onset fabry disease revealed by newborn screening. , 2006, American journal of human genetics.